NANOG and hepatocellular carcinoma: It was previously shown that dysregulated hypomethylation of the NANOG promoter is observed in the CD133 (+) population of human HCC cell lines.[35] Similar to these CD133 (+) cell lines, we observed primary TICs were hypomethylated in the Nanog promoter proximal region, consistent with the observed higher expression levels of NANOG (Figure S7, Supporting Information)).